Zydus Lifesciences to pursue acquisitions in specialty, rare diseases

Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology business in the US. The company reported robust financial growth for the fourth quarter of 2025-26. Zydus also announced a share buyback and a dividend. Future growth is expected from its specialty portfolio.